AbbVie (ABBV) - Attractive long-term investment from the healthcare sector
Why $ABBV+1.6% is an interesting choice:
- The success of new drugs:
- Skyrizi and Rinvoq offset losses from Humira.
- Sales for Skyrizi up 48% and Rinvoq up 59%.
- Promising growth potential for$ABBV+1.6% :
- The $10 billion acquisition of ImmunoGen and the planned $8.7 billion acquisition of Cerevel Therapeutics.
- CEO Richard A. Gonzalez expects strong growth starting in 2025.
- Over the past three years, AbbVie has generated more than $68 billion in free cash flow.
- Modest valuation and high dividend:
- Shares trade at 15 times future earnings with a PEG ratio of 0.4.
- The dividend yields 3.8%, more than double the S&P 500 average.
🌟 AbbVie is an attractive long-term investment with growth potential and stable returns!💊📈
For me, this is a very high quality company that last year and this year will reduce earnings per share. However, growth should return in the coming years. The dividend is also attractive. The potential for the future is certainly there.